Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.

Participants needed: 210
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Mar 6, 2026Locations: 1
Eligibility criteria

Histologically or pathologically confirmed solid tumors with RAS mutation via mo... [+3]

Presence of central nervous system (CNS) metastases; however, subjects with prev... [+3]

Read more
Status: Not yet recruiting

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.

Participants needed: 207
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Sep 19, 2025
Eligibility criteria

Key Inclusion Criteria [+6]

Current participation in another therapeutic clinical trial. [+5]

Read more
Status: Recruiting

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Participants needed: 101
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Jul 14, 2025Locations: 1
Eligibility criteria

Adult patients age 18 years or older. [+4]

Current participation in another therapeutic clinical trial. [+4]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients. Participants will be treated with low-dose JYP0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose JYP0061. Efficacy and safety evaluations will be conducted according to the protocol.

Participants needed: 35
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Nov 20, 2024Locations: 1
Eligibility criteria

Neuromyelitis spectrum disease (NMOSD) patients according to 2015 International... [+4]

Pregnant or lactating women; [+3]

Read more
Status: Recruiting

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.

Participants needed: 210
Trial details
Phase: Phase 2, Phase 3Age: 40-80Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Nov 19, 2024Locations: 1
Eligibility criteria

Ability to understand and sign written informed consent. [+4]

Forced expiratory volume in one second (FEV1)/FVC ratio <0.7 after administratio... [+6]

Read more